|
SI2591114T1
(sl)
|
2010-07-06 |
2016-10-28 |
Glaxosmithkline Biologicals S.A. |
Imunizacija velikih sesalcev z majhnimi odmerki RNA
|
|
US11291635B2
(en)
|
2010-07-06 |
2022-04-05 |
Glaxosmithkline Biological Sa |
Virion-like delivery particles for self-replicating RNA molecules
|
|
EP3449910A1
(en)
|
2010-07-06 |
2019-03-06 |
GlaxoSmithKline Biologicals S.A. |
Cationic oil-in-water emulsions
|
|
ES2646669T3
(es)
|
2010-07-06 |
2017-12-14 |
Glaxosmithkline Biologicals Sa |
Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
|
|
AU2011276234B2
(en)
|
2010-07-06 |
2016-02-25 |
Glaxosmithkline Biologicals S.A. |
Liposomes with lipids having an advantageous pKa- value for RNA delivery
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2012031043A1
(en)
|
2010-08-31 |
2012-03-08 |
Novartis Ag |
Pegylated liposomes for delivery of immunogen-encoding rna
|
|
BR112013004879A2
(pt)
*
|
2010-08-31 |
2018-04-24 |
Novartis Ag |
lipossomas pequenos para entrega de rna que codifica imunogénio
|
|
ES3005233T3
(en)
|
2010-10-01 |
2025-03-14 |
Modernatx Inc |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
EP3520813B1
(en)
*
|
2010-10-11 |
2023-04-19 |
GlaxoSmithKline Biologicals S.A. |
Antigen delivery platforms
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
DK3336082T3
(da)
|
2011-06-08 |
2020-04-27 |
Translate Bio Inc |
Spaltelige lipider
|
|
PT2717893T
(pt)
|
2011-06-08 |
2019-08-20 |
Translate Bio Inc |
Composições de nanopartículas lipídicas e métodos para transferência de arnm
|
|
AU2012280901B2
(en)
|
2011-07-06 |
2016-11-10 |
Glaxosmithkline Biologicals S.A. |
Oil-in-water emulsions that contain nucleic acids
|
|
EP3854413A1
(en)
|
2011-07-06 |
2021-07-28 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
|
EP4014966A1
(en)
*
|
2011-07-06 |
2022-06-22 |
GlaxoSmithKline Biologicals S.A. |
Liposomes having useful n:p ratio for delivery of rna molecules
|
|
RU2649133C2
(ru)
|
2011-07-06 |
2018-03-29 |
Новартис Аг |
Катионные эмульсии масло-в-воде
|
|
SG11201400250UA
(en)
*
|
2011-08-31 |
2014-03-28 |
Novartis Ag |
Pegylated liposomes for delivery of immunogen-encoding rna
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2763701B1
(en)
|
2011-10-03 |
2018-12-19 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
US20140271829A1
(en)
*
|
2011-10-11 |
2014-09-18 |
Anders Lilja |
Recombinant self-replicating polycistronic rna molecules
|
|
JP2015501844A
(ja)
|
2011-12-16 |
2015-01-19 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
CN108949772A
(zh)
|
2012-04-02 |
2018-12-07 |
现代泰克斯公司 |
用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
WO2013185069A1
(en)
|
2012-06-08 |
2013-12-12 |
Shire Human Genetic Therapies, Inc. |
Pulmonary delivery of mrna to non-lung target cells
|
|
WO2014028429A2
(en)
|
2012-08-14 |
2014-02-20 |
Moderna Therapeutics, Inc. |
Enzymes and polymerases for the synthesis of rna
|
|
ES2921623T3
(es)
|
2012-11-26 |
2022-08-30 |
Modernatx Inc |
ARN modificado terminalmente
|
|
WO2014108515A1
(en)
|
2013-01-10 |
2014-07-17 |
Novartis Ag |
Influenza virus immunogenic compositions and uses thereof
|
|
JP2016504050A
(ja)
|
2013-01-17 |
2016-02-12 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
細胞表現型の改変のためのシグナルセンサーポリヌクレオチド
|
|
US20160024181A1
(en)
|
2013-03-13 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US11155572B2
(en)
|
2013-03-15 |
2021-10-26 |
Glaxosmithkline Biologicals Sa |
RNA purification methods
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
HUE056760T2
(hu)
|
2013-07-11 |
2022-03-28 |
Modernatx Inc |
A CRISPR-hez kapcsolódó fehérjéket és a szintetikus SGRNS-ket kódoló szintetikus polinukleotidokat tartalmazó készítmények és felhasználási módjaik
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
US20160194625A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
EP3065703A1
(en)
*
|
2013-11-08 |
2016-09-14 |
Tyrx, Inc. |
Polymeric drug delivery system for treating surgical complications
|
|
WO2015144732A2
(en)
*
|
2014-03-25 |
2015-10-01 |
Yale University |
Uses of parasite macrophage migration inhibitory factors
|
|
DK3134131T3
(en)
|
2014-04-23 |
2022-02-07 |
Modernatx Inc |
Nucleic acid vaccines
|
|
EP2974739A1
(en)
|
2014-07-15 |
2016-01-20 |
Novartis AG |
RSVF trimerization domains
|
|
US11571472B2
(en)
|
2014-06-13 |
2023-02-07 |
Glaxosmithkline Biologicals Sa |
Immunogenic combinations
|
|
EP3169693B1
(en)
|
2014-07-16 |
2022-03-09 |
ModernaTX, Inc. |
Chimeric polynucleotides
|
|
WO2016014846A1
(en)
|
2014-07-23 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
EP3061826A1
(en)
|
2015-02-27 |
2016-08-31 |
Novartis AG |
Flavivirus replicons
|
|
EP3173092B1
(en)
|
2015-04-22 |
2019-06-26 |
CureVac AG |
Rna containing composition for treatment of tumor diseases
|
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
|
MA42502A
(fr)
|
2015-07-21 |
2018-05-30 |
Modernatx Inc |
Vaccins contre une maladie infectieuse
|
|
RS63030B1
(sr)
|
2015-09-17 |
2022-04-29 |
Modernatx Inc |
Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava
|
|
EP3359670B2
(en)
|
2015-10-05 |
2024-02-14 |
ModernaTX, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
WO2017070601A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
|
TN2018000154A1
(en)
*
|
2015-10-22 |
2019-10-04 |
Modernatx Inc |
Respiratory syncytial virus vaccine
|
|
EP3365009A4
(en)
*
|
2015-10-22 |
2019-07-03 |
ModernaTX, Inc. |
VACCINES AGAINST HERPES SIMPLEX VIRUS
|
|
AU2016342048B2
(en)
*
|
2015-10-22 |
2022-09-08 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
EP3364981A4
(en)
*
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
AU2016342376A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Sexually transmitted disease vaccines
|
|
CA3007955A1
(en)
|
2015-12-10 |
2017-06-15 |
Modernatx, Inc. |
Lipid nanoparticles for delivery of therapeutic agents
|
|
JP7114465B2
(ja)
|
2015-12-22 |
2022-08-08 |
モデルナティエックス インコーポレイテッド |
薬剤の細胞内送達のための化合物および組成物
|
|
WO2017112943A1
(en)
|
2015-12-23 |
2017-06-29 |
Modernatx, Inc. |
Methods of using ox40 ligand encoding polynucleotides
|
|
WO2017120612A1
(en)
|
2016-01-10 |
2017-07-13 |
Modernatx, Inc. |
Therapeutic mrnas encoding anti ctla-4 antibodies
|
|
US10022436B2
(en)
|
2016-01-11 |
2018-07-17 |
Verndari, Inc. |
Microneedle compositions and methods of using same
|
|
WO2017162265A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Trans-replicating rna
|
|
US12128113B2
(en)
|
2016-05-18 |
2024-10-29 |
Modernatx, Inc. |
Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
|
|
US10967057B2
(en)
|
2016-06-02 |
2021-04-06 |
Glaxosmithkline Biologicals S.A. |
Zika viral antigen constructs
|
|
EP3518966A1
(en)
|
2016-09-29 |
2019-08-07 |
GlaxoSmithKline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
AU2017345766A1
(en)
|
2016-10-21 |
2019-05-16 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
CN110167587A
(zh)
|
2016-11-11 |
2019-08-23 |
摩登纳特斯有限公司 |
流感疫苗
|
|
BE1025121B1
(fr)
|
2016-11-17 |
2018-11-05 |
Glaxosmithkline Biologicals Sa |
Constructions antigeniques du virus zika
|
|
EP3551193A4
(en)
|
2016-12-08 |
2020-08-19 |
Modernatx, Inc. |
NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
|
|
TW202428301A
(zh)
|
2017-02-28 |
2024-07-16 |
法商賽諾菲公司 |
治療性rna
|
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
|
MA47787A
(fr)
|
2017-03-15 |
2020-01-22 |
Modernatx Inc |
Vaccin contre le virus respiratoire syncytial
|
|
CA3056133A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
KR20190132405A
(ko)
|
2017-03-15 |
2019-11-27 |
모더나티엑스, 인크. |
치료제의 세포내 전달을 위한 화합물 및 조성물
|
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
ES3020935T3
(en)
|
2017-03-15 |
2025-05-23 |
Modernatx Inc |
Lipid nanoparticle formulation
|
|
TW201907937A
(zh)
|
2017-05-08 |
2019-03-01 |
美商葛利史東腫瘤科技公司 |
阿爾法病毒新抗原載體
|
|
ES2952779T3
(es)
|
2017-05-18 |
2023-11-06 |
Modernatx Inc |
ARN mensajero modificado que comprende elementos de ARN funcionales
|
|
US11421011B2
(en)
|
2017-05-18 |
2022-08-23 |
Modernatx, Inc. |
Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
|
|
JP7402503B2
(ja)
|
2017-06-14 |
2023-12-21 |
テクニスチェ ユニベルシタト ドレスデン |
デザイナーｄｎａ組換え酵素を利用したゲノムを遺伝的に改変するための方法及び手段
|
|
EP3638292A1
(en)
|
2017-06-14 |
2020-04-22 |
ModernaTX, Inc. |
Polynucleotides encoding coagulation factor viii
|
|
US12077501B2
(en)
|
2017-06-14 |
2024-09-03 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
WO2018232357A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna formulations
|
|
WO2019023566A1
(en)
|
2017-07-28 |
2019-01-31 |
Janssen Vaccines & Prevention B.V. |
METHODS AND COMPOSITIONS FOR PROVIDING IMMUNIZATION AGAINST Heterologous ARNREP
|
|
US11639329B2
(en)
|
2017-08-16 |
2023-05-02 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
|
US10653767B2
(en)
|
2017-09-14 |
2020-05-19 |
Modernatx, Inc. |
Zika virus MRNA vaccines
|
|
EP3461497A1
(en)
|
2017-09-27 |
2019-04-03 |
GlaxoSmithKline Biologicals S.A. |
Viral antigens
|
|
WO2019104160A2
(en)
|
2017-11-22 |
2019-05-31 |
Modernatx, Inc. |
Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
|
|
EP3714048B1
(en)
|
2017-11-22 |
2025-04-09 |
ModernaTX, Inc. |
Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
|
|
JP7424976B2
(ja)
|
2017-11-22 |
2024-01-30 |
モダーナティエックス・インコーポレイテッド |
プロピオン酸血症の治療用のプロピオニルＣｏＡカルボキシラーゼアルファ及びベータサブユニットをコードするポリヌクレオチド
|
|
US11020476B2
(en)
|
2017-12-19 |
2021-06-01 |
Janssen Sciences Ireland Unlimited Company |
Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
|
|
US11389531B2
(en)
|
2017-12-19 |
2022-07-19 |
Janssen Sciences Ireland Unlimited Company |
Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
|
|
EA202091513A1
(ru)
|
2017-12-19 |
2020-09-09 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Вакцины против вируса гепатита b (hbv) и их применение
|
|
MX2020006225A
(es)
|
2017-12-20 |
2020-12-07 |
Glaxosmithkline Biologicals Sa |
Constructos antigenicos del virus de epstein-barr.
|
|
JP7653013B2
(ja)
|
2018-01-04 |
2025-03-28 |
アイコニック セラピューティクス リミテッド ライアビリティ カンパニー |
抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法
|
|
EP3735270A1
(en)
|
2018-01-05 |
2020-11-11 |
Modernatx, Inc. |
Polynucleotides encoding anti-chikungunya virus antibodies
|
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
|
US11904081B2
(en)
|
2018-05-11 |
2024-02-20 |
Lupagen, Inc. |
Systems and methods for closed loop, real-time modifications of patient cells
|
|
US20210346306A1
(en)
|
2018-05-23 |
2021-11-11 |
Modernatx, Inc. |
Delivery of dna
|
|
EP3581201A1
(en)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 proteins and uses thereof
|
|
US20220184185A1
(en)
|
2018-07-25 |
2022-06-16 |
Modernatx, Inc. |
Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
|
|
CN113164584A
(zh)
|
2018-08-17 |
2021-07-23 |
葛兰素史密丝克莱恩生物有限公司 |
免疫原性组合物及其用途
|
|
WO2020047201A1
(en)
|
2018-09-02 |
2020-03-05 |
Modernatx, Inc. |
Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
|
|
WO2020056155A2
(en)
|
2018-09-13 |
2020-03-19 |
Modernatx, Inc. |
Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
|
|
EP3849595B1
(en)
|
2018-09-13 |
2025-11-19 |
ModernaTX, Inc. |
Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease
|
|
US20220401584A1
(en)
|
2018-09-14 |
2022-12-22 |
Modernatx, Inc. |
Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
|
|
WO2020061367A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
AU2019345067A1
(en)
|
2018-09-19 |
2021-04-08 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
|
US12151029B2
(en)
|
2018-09-19 |
2024-11-26 |
Modernatx, Inc. |
PEG lipids and uses thereof
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
EP3856233A1
(en)
|
2018-09-27 |
2021-08-04 |
Modernatx, Inc. |
Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
KR20250171410A
(ko)
|
2019-03-08 |
2025-12-08 |
메사추세츠 인스티튜트 오브 테크놀로지 |
합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도
|
|
WO2020190750A1
(en)
|
2019-03-15 |
2020-09-24 |
Modernatx, Inc. |
Hiv rna vaccines
|
|
CN114375190A
(zh)
|
2019-05-08 |
2022-04-19 |
阿斯利康(瑞典)有限公司 |
用于皮肤和伤口的组合物及其使用方法
|
|
MX2021014525A
(es)
|
2019-05-30 |
2022-03-17 |
Gritstone Bio Inc |
Adenovirus modificados.
|
|
WO2020255010A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
|
|
KR20220041080A
(ko)
|
2019-06-18 |
2022-03-31 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
B형 간염 바이러스(hbv) 백신 및 항-pd-1 또는 항-pc-l1 항체의 조합
|
|
MA56520A
(fr)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Co |
Construction de l'interleukine 12 recombinante et ses utilisations
|
|
US20220305117A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
|
|
AU2020296372A1
(en)
|
2019-06-18 |
2022-02-17 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis B virus (HBV) vaccines and anti-PD-1 antibody
|
|
AU2020295807A1
(en)
*
|
2019-06-20 |
2022-02-17 |
Janssen Sciences Ireland Unlimited Company |
Lipid nanoparticle or liposome delivery of hepatitis B virus (HBV) vaccines
|
|
CN114206909A
(zh)
|
2019-07-21 |
2022-03-18 |
葛兰素史克生物有限公司 |
治疗性病毒疫苗
|
|
CA3155015A1
(en)
|
2019-09-19 |
2021-03-25 |
Modernatx, Inc. |
Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
MX2022003269A
(es)
|
2019-09-19 |
2022-07-04 |
Modernatx Inc |
Compuestos lipidicos de cola ramificada y composiciones para la administracion intracelular de agentes terapeuticos.
|
|
CN114980920A
(zh)
|
2019-11-18 |
2022-08-30 |
詹森生物科技公司 |
基于突变体calr和jak2的疫苗及其用途
|
|
CA3171231A1
(en)
|
2020-03-09 |
2021-09-16 |
Sean Michael Sullivan |
Compositions and methods for inducing immune responses
|
|
KR20230013237A
(ko)
|
2020-03-09 |
2023-01-26 |
다이나박스 테크놀로지 코퍼레이션 |
Tlr9 효능제를 포함하는 대상포진 백신
|
|
EP4135761A1
(en)
|
2020-04-16 |
2023-02-22 |
GlaxoSmithKline Biologicals S.A. |
Sars cov-2 spike protein construct
|
|
EP4153223A1
(en)
*
|
2020-05-20 |
2023-03-29 |
Flagship Pioneering Innovations VI, LLC |
Immunogenic compositions and uses thereof
|
|
CA3184474A1
(en)
|
2020-06-01 |
2021-12-09 |
Modernatx, Inc. |
Phenylalanine hydroxylase variants and uses thereof
|
|
US20230234992A1
(en)
|
2020-06-05 |
2023-07-27 |
Glaxosmithkline Biologicals Sa |
Modified betacoronavirus spike proteins
|
|
WO2022002783A1
(en)
|
2020-06-29 |
2022-01-06 |
Glaxosmithkline Biologicals Sa |
Adjuvants
|
|
WO2022009052A2
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
CA3188801A1
(en)
|
2020-07-08 |
2022-01-13 |
Janssen Sciences Ireland Unlimited Company |
Rna replicon vaccines against hbv
|
|
JP7798855B2
(ja)
|
2020-07-16 |
2026-01-14 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子に使用するためのカチオン性脂質
|
|
EP4192496A4
(en)
|
2020-08-06 |
2025-01-01 |
Gritstone bio, Inc. |
MULTIEPITOP VACCINE CASSETTES
|
|
CN116171150A
(zh)
|
2020-08-14 |
2023-05-26 |
阿克丘勒斯治疗公司 |
冻干脂质纳米颗粒的方法
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
WO2022104131A1
(en)
|
2020-11-13 |
2022-05-19 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
WO2022133230A1
(en)
|
2020-12-18 |
2022-06-23 |
Janssen Pharmaceuticals, Inc. |
Combination therapy for treating hepatitis b virus infection
|
|
US20240299309A1
(en)
*
|
2020-12-22 |
2024-09-12 |
CureVac SE |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
WO2022137128A2
(en)
|
2020-12-23 |
2022-06-30 |
Glaxosmithkline Biologicals Sa |
Self-amplifying messenger rna
|
|
WO2022146654A1
(en)
|
2020-12-28 |
2022-07-07 |
Janssen Pharmaceuticals, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
|
EP4032546A1
(en)
|
2021-01-20 |
2022-07-27 |
GlaxoSmithKline Biologicals S.A. |
Therapeutic viral vaccine
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
WO2022204370A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
|
|
US20240226025A1
(en)
|
2021-03-24 |
2024-07-11 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
|
WO2022204390A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
|
|
WO2022204380A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
|
|
WO2022204371A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
|
|
MX2023011400A
(es)
|
2021-03-26 |
2023-10-09 |
Glaxosmithkline Biologicals Sa |
Composiciones inmunogenicas.
|
|
EP4346894A1
(en)
|
2021-05-24 |
2024-04-10 |
GlaxoSmithKline Biologicals S.A. |
Adjuvants
|
|
US20240272143A1
(en)
|
2021-06-09 |
2024-08-15 |
Glaxosmithkline Biologicals Sa |
Release assay for determining potency of self-amplifying rna drug product and methods for using
|
|
US20240384277A1
(en)
|
2021-06-15 |
2024-11-21 |
Modernatx, Inc. |
Engineered polynucleotides for cell-type or microenvironment-specific expression
|
|
US20240376445A1
(en)
|
2021-06-22 |
2024-11-14 |
Modernatx, Inc. |
Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
|
|
WO2023020994A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
EP4387597A1
(en)
|
2021-08-16 |
2024-06-26 |
GlaxoSmithKline Biologicals SA |
Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
|
|
WO2023021421A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Low-dose lyophilized rna vaccines and methods for preparing and using the same
|
|
WO2023020993A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023020992A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
CA3229889A1
(en)
|
2021-09-03 |
2023-03-09 |
Glaxosmithkline Biologicals Sa |
Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
|
|
WO2023056044A1
(en)
|
2021-10-01 |
2023-04-06 |
Modernatx, Inc. |
Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
|
|
CN115960922A
(zh)
*
|
2021-10-09 |
2023-04-14 |
吴可行 |
自复制rna分子设计及其应用
|
|
AU2022386716A1
(en)
|
2021-11-15 |
2024-05-02 |
Technische Universität Dresden |
Site-specific recombinases for efficient and specific genome editing
|
|
CA3242402A1
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2023183909A2
(en)
|
2022-03-25 |
2023-09-28 |
Modernatx, Inc. |
Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
|
|
WO2023198815A1
(en)
|
2022-04-14 |
2023-10-19 |
Janssen Vaccines & Prevention B.V. |
Sequential administration of adenoviruses
|
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
|
CN117070464A
(zh)
*
|
2022-05-16 |
2023-11-17 |
上海行深生物科技有限公司 |
蛋白包裹自复制rna及其制备方法
|
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
|
WO2023242817A2
(en)
|
2022-06-18 |
2023-12-21 |
Glaxosmithkline Biologicals Sa |
Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
|
|
MA71619A
(fr)
|
2022-07-26 |
2025-05-30 |
Modernatx, Inc. |
Polynucléotides modifiés pour la régulation temporelle de l'expression
|
|
CA3267272A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
FLU VIRUS VACCINES
|
|
AU2023383367A1
(en)
|
2022-11-18 |
2025-05-29 |
Trustees Of Boston University |
Self-replicating rna and uses thereof
|
|
WO2024133160A1
(en)
|
2022-12-19 |
2024-06-27 |
Glaxosmithkline Biologicals Sa |
Hepatitis b compositions
|
|
EP4658239A1
(en)
|
2023-02-03 |
2025-12-10 |
GlaxoSmithKline Biologicals S.A. |
Rna formulation
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
WO2024197033A1
(en)
|
2023-03-21 |
2024-09-26 |
Modernatx, Inc. |
Polynucleotides encoding relaxin for the treatment of heart failure
|
|
WO2024218137A1
(en)
|
2023-04-17 |
2024-10-24 |
Technische Universität Dresden |
Novel recombinase enzymes for site-specific dna-recombination
|
|
EP4701657A1
(en)
|
2023-04-27 |
2026-03-04 |
GlaxoSmithKline Biologicals S.A. |
Influenza virus vaccines
|
|
WO2024223728A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
AU2024265267A1
(en)
|
2023-05-03 |
2025-11-20 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
EP4480490A1
(en)
|
2023-06-23 |
2024-12-25 |
Medizinische Hochschule Hannover |
Brick1 for use in treating myocardial diseases
|
|
CN121532514A
(zh)
|
2023-07-07 |
2026-02-13 |
上海环码生物医药有限公司 |
用于季节性流感的环状rna疫苗及使用方法
|
|
CN116726036B
(zh)
*
|
2023-07-27 |
2025-12-26 |
中国水产科学研究院黑龙江水产研究所 |
Nm107在抗传染性胰脏坏死病毒中的应用
|
|
WO2025045142A1
(en)
|
2023-08-29 |
2025-03-06 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
AU2024332500A1
(en)
|
2023-09-01 |
2026-03-19 |
Seamless Therapeutics Gmbh |
Method for the production of a target-specific large serine recombinase
|
|
WO2025072482A1
(en)
|
2023-09-27 |
2025-04-03 |
Modernatx, Inc. |
Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof
|
|
US20250145973A1
(en)
|
2023-10-16 |
2025-05-08 |
Technische Universität Dresden Körperschaft Des Öffentlichen Rechts |
Conditioned dna modifying enzyme comprising heterologous dna binding domain
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025229572A1
(en)
|
2024-05-01 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
|
|
WO2025255199A1
(en)
|
2024-06-05 |
2025-12-11 |
Modernatx, Inc. |
Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof
|
|
WO2025252950A1
(en)
|
2024-06-07 |
2025-12-11 |
Technische Universität Dresden Körperschaft Des Öffentlichen Rechts |
Method for producing spacer-specific dna recombining enzymes
|
|
US20260049306A1
(en)
|
2024-07-25 |
2026-02-19 |
Technische Universität Dresden Körperschaft Des Öffentlichen Rechts |
Modifying nucleic acid sequences having asymmetric target sites
|
|
CN120310792B
(zh)
*
|
2025-02-27 |
2026-01-30 |
复旦大学附属肿瘤医院 |
一种帽非依赖的线性mRNA表达系统及其应用
|